Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Rompe JD, Segal NA, Cacchio A, Furia JP, Morral A, Maffulli N
Furthermore, across several cellular models, incretin receptor agonists have been reported to suppress pro-fibrotic signalling pathways, including TGF-/Smad signalling, and NFB activation, leading to reduced expression of ECM proteins
This group includes semaglutide (Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), liraglutide, and dulaglutide
Targeting these amino acid-driven metabolic circuits may offer novel therapeutic opportunities in fibrotic diseases such as IPF, where metabolic vulnerabilities can be exploited to disrupt fibroblast activation and excessive ECM remodeling
Current data suggests that this affects around 1 in 10 people aged 75 or over, and 1 in 20 people aged 65 to 74 in the UK
A smaller liraglutide trial demonstrated no reduction in A burden or cognitive change though it preserved brain glucose metabolism
.png)
